drugset / Trial / NCT05326516
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
Timeline
- Start
- 2022-03-09
- Primary completion
- 2024-07-29
- Completion
- 2024-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revumenib | Small molecule | — | — |
| Background | Calaspargase Pegol | Protein / enzyme biologic | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Daunorubicin | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Pegaspargase | Protein / enzyme biologic | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Vincristine | Small molecule | — | — |